S. Sirko

Simple Demographic Model to Predict Multiple Cardiometabolic Risk Factors in Two Well-Known Observational Cohorts

D. Hoaglin, C. Hollenbeak, P. Wilson, 2007 .

Transcription, translation and secretion of interleukin 1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5‐lipoxygenase inhibitor

C. Dinarello, R. Schindler, S. Weisman, 1991, European journal of immunology.

Perioperative Bridging Therapy with Enoxaparin in Patients Requiring Interruption of Long-Term Oral Anticoagulant Therapy: A Multicenter Cohort Study.

A. Turpie, A. Dunn, S. Sirko, 2004 .

An antibody to a 17 amino acid synthetic peptide of the type I interleukin-1 receptor preferentially blocks interleukin-1 beta binding.

T. Ikejima, C. Dinarello, B. D. Clark, 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non‐steroidal anti‐inflammatory drugs to pigs: a model for human gastrointestinal disease

K. Rainsford, S. Sirko, P. Stetsko, 2003, The Journal of pharmacy and pharmacology.

New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent.

R. Darolia, S. Green, K. Wehmeyer, 1998, Journal of medicinal chemistry.

NSAID-Induced Mucosal Injury: Analysis of Gastric Toxicity with New Generation NSAIDs: Ulcerogenicity Compared with Ulcer Healing

F. Halter, K. Rainsford, S. Sirko, 1997, The Yale Journal of Biology and Medicine.